AbbVie (ABBV) Expands Its Pipeline With New AI Drug Discovery Partnerships
ETFs Are Net Sellers of AbbVie (ABBV) on Nov. 12
AbbVie (ABBV) Stock Looks Below Fair Value After Strong Cash Flow Growth
How Did AbbVie's Immunology Franchise Fare in Q3?
Coca-Cola or AbbVie: The One Dividend Stock I’d Hold for the Next 20 Years
AbbVie (ABBV) Reports Positive Phase 3 QULIPTA Migraine Trial Results
ABBV Stock Rises More Than 4% in a Month: Time to Buy, Hold or Sell?
Can AbbVie (ABBV) Justify Its Valuation After Raised Guidance And Strong Results?
While pharma peers stumble, AbbVie defeated the patent cliff
Reported Sunday, Allergan Aesthetics’ HALO Interim Results Show 95.7% Of 25 Adults On GLP-1 Medications Satisfied Or Very Satisfied They Still Looked Like Themselves After HA Injectables, With 39.6-Point FACE-Q Gain
Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications
Is AbbVie Inc. (ABBV) the Best Healthcare Stock to Buy Following the 2026 Democratic Midterm Sweep?
Why Is AbbVie (ABBV) Spending $1.37 Billion On Pipeline And UK Research?
Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today
Are Wall Street Analysts Bullish on AbbVie Stock?
AbbVie (ABBV) Stock Climbs As Q3 Earnings Fuel Growth Case
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?
AbbVie bolsters UK R&D presence, inks $1.38bn IBD deal with Nxera
AbbVie Hit a New High After Earnings. There’s More Upside Left.
AbbVie inks $757m migraine-focused deal with Brise Pharmaceuticals
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.